StockNews.AI · 7 days
Zepp Health reported Q1 2026 revenue of $51.5 million, up 33.8% year over year, with a 37.7% gross margin. The company guided Q2 revenue to $63–$68 million, signaling continued top-line strength, and extended its HYROX exclusive global partnership for three years. New Amazfit Balance 3/Ultra and Cheetah 2 models aim to drive premiumization and deeper ecosystem engagement, potentially improving profitability over time.
The company posted solid YoY revenue growth, modest gross-margin expansion, and raised 2026 top-line guidance while extending HYROX with a global footprint and launching higher-end products. Combined with a share-repurchase program, these elements can improve investor sentiment and potentially lift ZEPP shares in the near term, despite ongoing losses.
ZEPP likely moves higher in the near term on 2026 guidance and HYROX deal; 1–3 quarters view.
Category: Earnings. The release centers on quarterly results, growth drivers, and near-term outlook, aligning with a typical earnings narrative for Zepp Health and its premiumization strategy.